Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
Neubewertung voraus? Wird die Aktivierung der EU-Lizenz zum Kurs-Katalysator für die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D2TK | ISIN: CH1216478797 | Ticker-Symbol: ZX6
Tradegate
23.07.25 | 17:37
89,30 Euro
+1,02 % +0,90
1-Jahres-Chart
DSM-FIRMENICH AG Chart 1 Jahr
5-Tage-Chart
DSM-FIRMENICH AG 5-Tage-Chart
RealtimeGeldBriefZeit
90,1090,5422:59
90,1890,6022:00
GlobeNewswire (Europe)
612 Leser
Artikel bewerten:
(2)

dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025

Press Release

dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2025

Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2025

dsm-firmenich, innovators in nutrition, health, and beauty, announces that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting today, including the Management Report, the consolidated financial statements as well as the Sustainability Report 2024.

Key highlights include:

  • Thomas Leysen was re-elected and confirmed as Chairman of the Board.
  • Patrick Firmenich, Sze Cotte-Tan, Antoine Firmenich, Erica Mann, Carla Mahieu, Frits van Paasschen, André Pometta, John Ramsay, Richard Ridinger, and Corien Wortmann were re-elected to the board.
  • Shareholders approved the dividend of €2.50 per share. The dividend will be paid as of May 16, 2025, and the last trading day with entitlement to receive the payment is May 7, 2025.
  • Shareholders approved a maximum total amount of remuneration of €3,682,582 for the Board of Directors for the year through the 2026 AGM.
  • Shareholders approved a maximum total amount of remuneration of €43,982,072 for the Executive Committee for the financial year 2026.
  • Shareholders also endorsed the 2024 Compensation Report in a consultative vote.
  • Carla Mahieu, Thomas Leysen, Frits van Paasschen, and André Pometta were re-elected to the Compensation Committee. The Board intends to appoint Carla Mahieu as Chair of the committee.
  • PricewaterhouseCoopers AG was elected as auditor.
  • Christian Hochstrasser was re-elected as the independent proxy.
  • An amendment to the capital band provision in the Articles of Association allowing the Board of Directors to decrease the share capital one or several times within the limit of 90% of the current share capital. This authorization will be used to reduce the capital following the implementation of dsm-firmenich's share buyback program announced on February 13, 2025.

The shareholders in attendance, together with the votes represented by independent proxy, represented 72.72% of shares.

PDF version of this press release can be found here.

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world's growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for the planet. dsm-firmenich is a Swiss company with dual headquarters in Kaiseraugst, Switzerland and Maastricht, Netherlands, listed on the Euronext Amsterdam, with operations in almost 60 countries and revenues of more than €12 billion. With a diverse, worldwide team of nearly 30,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

For more information

Media relations
Robin Roothans
tel. +41
Investor relations
Dave Huizing
tel. +31

Forward-looking statements
This press release may contain forward-looking statements with respect to dsm-firmenich's future performance and position. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance, transaction progress and positions to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment

  • Press release_dsm shareholders approve all resolutions at Annual General Meeting 2025_20250506_FINAL (https://ml-eu.globenewswire.com/Resource/Download/471fbe4d-2454-4c01-9494-c30d45bbb0fb)

© 2025 GlobeNewswire (Europe)
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.